Article
Endocrinology & Metabolism
Giulia Puliani, Valeria Hasenmajer, Ilaria Simonelli, Valentina Sada, Riccardo Pofi, Marianna Minnetti, Alessia Cozzolino, Nicola Napoli, Patrizio Pasqualetti, Daniele Gianfrilli, Andrea M. Isidori
Summary: This meta-analysis evaluated the efficacy and safety of PTH1-34 and PTH1-84 in treating chronic hypoparathyroidism. The results showed that PTH therapy can normalize serum phosphate and urinary calcium excretion, reduce calcium and vitamin D use, and improve quality of life.
JOURNAL OF BONE AND MINERAL RESEARCH
(2022)
Article
Endocrinology & Metabolism
K. Eastman, M. Gerlach, I. Piec, J. Greeves, W. Fraser
Summary: This meta-analysis evaluated the evidence for the use of parathyroid hormone (PTH) analogues to improve fracture healing. PTH improved functional outcomes but did not affect fracture healing rate or reduce pain. The evidence for PTH analogue use in fracture healing is less clear in younger, non-osteoporotic patient populations, warranting further research.
OSTEOPOROSIS INTERNATIONAL
(2021)
Article
Endocrinology & Metabolism
Kelly L. Roszko, Tiffany Y. Hu, Lori C. Guthrie, Beth A. Brillante, Michaele Smith, Michael T. Collins, Rachel Gafni
Summary: Patients with hypoparathyroidism experience poor quality of life, including fatigue and brain fog. Treatment with PTH 1-34 had limited and non-sustained effects on improving quality of life, inconclusive changes in fatigue experience, and no change in the 6-minute walk test.
JOURNAL OF BONE AND MINERAL RESEARCH
(2022)
Article
Engineering, Biomedical
Zhiyuan Zou, Le Wang, Zhifei Zhou, Qing Sun, Delong Liu, Yan Chen, Hao Hu, Yu Cai, Sixiong Lin, Zhengran Yu, Bizhi Tan, Wei Guo, Zemin Ling, Xuenong Zou
Summary: The use of hydrogels containing PTH and nHAP can promote cranial bone regeneration by enhancing the expression of osteogenic-related proteins and facilitating osteogenic differentiation of BMSCs through the Notch signaling pathway. Implantation of the hydrogel into a rat cranial defect model showed efficient bone regeneration compared to using the hydrogel alone or nHAP alone, indicating a promising therapeutic effect of combining nHAP and PTH for bone regeneration.
BIOACTIVE MATERIALS
(2021)
Article
Critical Care Medicine
Tito Rocha, Amanda S. Cavalcanti, Ana Carolina Leal, Rhayra B. Dias, Rafaela Sartore da Costa, Gabriele de Oliveira Ribeiro, Joao Antonio Matheus Guimaraes, Maria Eugenia Leite Duarte
Summary: The study investigated the effects of teriparatide in acellular allograft treatment, indicating that it can promote new bone formation, enhance revitalization of allogeneic graft, and increase the frequency and osteogenic capacity of bone marrow stromal cells.
INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
(2021)
Article
Endocrinology & Metabolism
Sanchita Agarwal, Donald J. McMahon, Juliet Chen, Aiden V. Brossfield, Jason Fernando, John P. Bilezikian, Natalie E. Cusano, Mishaela R. Rubin
Summary: Hypoparathyroidism is a disorder characterized by low calcium levels, reduced parathyroid hormone, decreased bone remodeling, and increased bone density. Long-term treatment with PTH can reduce the need for calcium and active vitamin D supplements, maintain normal calcium levels, but lead to a decrease in bone mass.
JOURNAL OF BONE AND MINERAL RESEARCH
(2023)
Article
Endocrinology & Metabolism
Elisabeth Laurer, Johanna Gruenberger, Uvistra Naidoo, Roland Lanzersdorfer, Marlene Wimleitner, Katharina Tischlinger, Wolfgang Hoegler
Summary: Full-length recombinant human parathyroid hormone (rhPTH[1-84]) is effective in treating hypoparathyroidism, especially in patients refractory to conventional therapy. Dose optimization based on serum ionized calcium, urinary calcium-to-creatinine ratio, and 24-hour urinary calcium excretion is crucial for successful treatment.
Article
Medicine, General & Internal
Moon-Soo Han, Gwang-Jun Lee, Seul-Kee Lee, Jung-Kil Lee, Bong Ju Moon
Summary: This study investigates the relationship between clinical and radiological features and bone turnover markers (BTMs) during teriparatide therapy for osteoporotic vertebral compression fractures. The results show that the levels of serum osteocalcin and serum C-terminal telopeptide of type I collagen increase significantly, while parathyroid hormone (PTH) levels decrease significantly during the teriparatide treatment, suggesting the progression of fracture.
Article
Endocrinology & Metabolism
Sofia Ish-Shalom, Yoseph Caraco, Nariman Saba Khazen, Michal Gershinsky, Auryan Szalat, Phillip Schwartz, Ehud Arbit, Hillel Galitzer, Jonathan C. Y. Tang, Gregory Burshtein, Ariel Rothner, Arthur Raskin, Miriam Blum, William D. Fraser
Summary: Oral hPTH(1-34) treatment as an adjunct to standard therapy in adult patients with hypoparathyroidism was found to be safe and effective, allowing for a reduction in exogenous calcium supplementation while maintaining normocalcemia.
JOURNAL OF BONE AND MINERAL RESEARCH
(2021)
Review
Endocrinology & Metabolism
Nitchanant Kitcharanant, Nipon Chattipakorn, Siriporn C. Chattipakorn
Summary: This review compiled and discussed the mechanisms underlying the effects of parathyroid hormone (PTH) on bone healing following distraction osteogenesis. The findings showed that PTH accelerates bone regeneration through its involvement in cell proliferation and differentiation, bone formation, and callus remodeling.
OSTEOPOROSIS INTERNATIONAL
(2023)
Article
Orthopedics
Ashley R. Sweeney-Ambros, Amy E. Biggs, Nicholas D. Zimmerman, Kenneth A. Mann, Timothy A. Damron, Megan E. Oest
Summary: Post-radiotherapy bone fragility fractures are a common complication in cancer survivors. This study investigated the effects of combined delivery of parathyroid hormone and zoledronic acid on post-radiotherapy bone health and explored the potential use of parathyroid hormone as a bone marrow radioprotectant.
JOURNAL OF ORTHOPAEDIC RESEARCH
(2022)
Article
Chemistry, Physical
Paula Buzo Frigerio, Pedro Henrique Silva Gomes-Ferreira, Fabio Roberto De Souza Batista Juliana Moura, Idelmo Rangel Garcia Junior, Daniele Botticelli, Paulo Noronha Lisboa-Filho, Roberta Okamoto
Summary: This study evaluated the behavior of repaired bone in rats after extraction, focusing on the use of PTH (teriparatide) and Biogran (R) (a biomaterial). The results showed that the use of Biogran (R) with PTH improved bone quality in healthy rats, but did not have significant effects in orchiectomized rats. Further research is needed to determine more effective doses for postoperative bone formation.
Article
Dentistry, Oral Surgery & Medicine
Cansu Gul Koca, Sanaz Sadry, Hasan Asker, Muhammet Fatih cicek, Meryem Kosehasanogullari, Gurkan Kaya
Summary: The study demonstrates that intermittent administration of teriparatide (4mu g/kg once a day) enhances bone formation and mineralization, particularly effective in the midpalatal suture region.
ORTHODONTICS & CRANIOFACIAL RESEARCH
(2021)
Article
Dentistry, Oral Surgery & Medicine
Yuan Li, Yuran Qian, Hui Qiao, Weiyi Pan, Liang Xie, Yu Li
Summary: This study compared the effects of two osteoanabolic drugs, ABL and TPTD, on protecting alveolar bone in experimental periodontitis. The results showed that both ABL and TPTD reduced alveolar bone loss, with ABL having better osteoanabolic effects. In vitro experiments also demonstrated that ABL had higher alkaline phosphatase activity and osteoblastic gene expression compared to TPTD.
JOURNAL OF PERIODONTOLOGY
(2023)
Article
Dentistry, Oral Surgery & Medicine
Kang-Min Kim, Sehyang Kim, Hyun Hwang, Hey-Yun Kim, Dohyun Kim, Jung-Hyun Park, HyeRan Choo, Jin-Woo Kim
Summary: This case-control study examined the therapeutic effects of daily or weekly administration of teriparatide in the management of medication-related osteonecrosis of the jaw (MRONJ). The results showed that both daily and weekly injection groups had significantly faster healing compared to the control groups. Complete resolution of MRONJ was more likely in participants who received teriparatide injections.